CEO of Arterial Remodeling Technologies (“ART”) Will Update the Industry Today on the State of Bioresorbable Stents at the

PARIS--(BUSINESS WIRE)-- Arterial Remodeling Technologies (“ART”) announced today that its CEO, Machiel van der Leest, has been invited to present an update on the state of bioresorbable stents during today’s 23rd annual meeting of the ‘ESB’ (European Society of Biomaterials), at Tampere (Finland) University of Technology.

Prior to joining ART, Mr. van der Leest was a co-founder and Chief Technology Officer of Minvasys. During his career he has developed and successfully introduced 15 Class III medical devices, which required pre-market approval and a scientific review to ensure safety and effectiveness.

“This is a very exciting time in the development of bioresorbable stents,” said Mr. van der Leest. “Over time, these stents leave behind only the healed natural vessel, thereby permitting renewal of vasoreactivity along with the probability of vessel remodeling. Equally important to note is that late stent thrombosis is improbable because the stent has bioresorbed, and therefore extended antiplatelet therapy is unnecessary with this approach.”

About Arterial Remodeling Technologies (“ART”)

Arterial Remodeling Technologies (“ART”) is developing bioresorbable coronary polymer stents that promote the natural remodeling of an injured artery after angioplasty. The Company’s technology is based on intellectual property originating from three esteemed institutions: the Cleveland Clinic; the French national research institute, CNRS (Centre National de Recherche Scientifique), Montpellier, France; and, Descartes University, Paris.



CONTACT:

Ronald Trahan Associates Inc.
Ronald Trahan, APR, 508-359-4005, x108

KEYWORDS:   United States  Europe  North America  France

INDUSTRY KEYWORDS:   Health  Cardiology  Medical Devices

MEDIA:

Logo
 Logo

Suggested Articles

Frontage is Growing to Meet All Your Needs! Click Here to Learn About the Next Generation of Frontage.

Cara Care, a digital health startup focused on digestive diseases, raised $7 million to bring its mobile app to more patients in the U.S.

Investors looked past the headline success of Sci-B-Vac, zeroed in on the failure to achieve a secondary objective and sent VBI’s stock down 66%.